- Home
- GPK vs JAZZ Comparison
GPK vs JAZZ Comparison
Compare GPK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPK
- JAZZ
- Stock Information
- Founded
- GPK 2007
- JAZZ 2003
- Country
- GPK United States
- JAZZ Ireland
- Employees
- GPK 23000
- JAZZ N/A
- Industry
- GPK Containers/Packaging
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- GPK Consumer Discretionary
- JAZZ Health Care
- Exchange
- GPK Nasdaq
- JAZZ Nasdaq
- Market Cap
- GPK 6.4B
- JAZZ 6.7B
- IPO Year
- GPK 1992
- JAZZ 2007
- Fundamental
- Price
- GPK $21.14
- JAZZ $107.51
- Analyst Decision
- GPK Buy
- JAZZ Strong Buy
- Analyst Count
- GPK 8
- JAZZ 12
- Target Price
- GPK $28.40
- JAZZ $183.08
- AVG Volume (30 Days)
- GPK 3.2M
- JAZZ 730.8K
- Earning Date
- GPK 07-29-2025
- JAZZ 07-30-2025
- Dividend Yield
- GPK 2.08%
- JAZZ N/A
- EPS Growth
- GPK N/A
- JAZZ 49.21
- EPS
- GPK 2.05
- JAZZ 7.51
- Revenue
- GPK $8,668,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- GPK N/A
- JAZZ $6.05
- Revenue Next Year
- GPK $2.82
- JAZZ $4.68
- P/E Ratio
- GPK $10.30
- JAZZ $14.35
- Revenue Growth
- GPK N/A
- JAZZ 5.76
- 52 Week Low
- GPK $20.86
- JAZZ $95.49
- 52 Week High
- GPK $30.70
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- GPK 35.34
- JAZZ 45.65
- Support Level
- GPK $20.97
- JAZZ $106.56
- Resistance Level
- GPK $21.65
- JAZZ $109.43
- Average True Range (ATR)
- GPK 0.48
- JAZZ 2.66
- MACD
- GPK -0.04
- JAZZ -0.16
- Stochastic Oscillator
- GPK 10.12
- JAZZ 12.27
About GPK Graphic Packaging Holding Company
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Paperboard Manufacturing, Americas Paperboard Packaging, and Europe Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company generates revenue from the Americas, Europe and Asia Pacific regions.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.